The MedicX Fund Limited
08 August 2007
For immediate release 8 August 2007
MedicX Fund Limited
('MedicX Fund', 'the Fund' or 'the Company')
Acquisition Completion
MedicX Fund, (LSE: MXF, LSE: MXFC), the specialist investor in modern purpose
built primary healthcare properties, today announces that it has completed the
acquisition of a medical centre at Istead Rise which was completed in June 2007
and entered into a forward funding agreement to acquire a medical centre at
Warwick which is due to be completed by April 2008. The total acquisition cost
of the two properties is anticipated to be £4.215 million. The aggregate rent of
the two properties is £254,975 and DTZ Debenham Tie Leung, valuers to the MedicX
Fund, have valued the properties at £4.375 million net of 5.75% purchaser costs.
Both these properties form part of the C share portfolio. The total property
portfolio now comprises 41 properties: 35 Ordinary Share properties of which
three are under construction, and 6 C Share properties, of which two are under
construction.
End
For further information please contact:
MedicX Fund +44 (0) 1481 723450
Alison Simpson, Director
MedicX Group +44 (0) 1483 869500
Keith Maddin, Chairman
Mike Adams, Managing Director
Buchanan Communications +44 (0) 20 7466 5000
Charles Ryland / Lisa Baderoon / Mary-Jane Johnson
This information is provided by RNS
The company news service from the London Stock Exchange UWSRRBARWRRR
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.